Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1556.38% is 118% below its 5-year average of -712.78%, near the high end of its 5-year range (-8048.29%–-149.67%).
198.29% below its 12-month average of -521.77%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -304.15%.
EBITDA MARGIN
-1556.38%
EBITDA MARGIN AVG TTM
-521.77%
EBITDA MARGIN AVG 3Y
-1501.37%
EBITDA MARGIN AVG 5Y
-712.78%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-198.29%
CURRENT VS 3Y AVG
-3.66%
CURRENT VS 5Y AVG
-118.35%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Janux Therapeutics, Inc.
Market Cap
$1.04B
EBITDA Margin
-1556.38%
TTM Avg
-521.77%
3Y Avg
-1501.37%
5Y Avg
-712.78%
Market Cap
$1.04B
EBITDA Margin
-351.42%
TTM Avg
-184.18%
3Y Avg
-130.50%
5Y Avg
-161.84%
Market Cap
$1.04B
EBITDA Margin
-0.59%
TTM Avg
3.42%
3Y Avg
-15.99%
5Y Avg
-18.77%
Market Cap
$1.03B
EBITDA Margin
13.41%
TTM Avg
11.95%
3Y Avg
15.57%
5Y Avg
17.13%
Market Cap
$1.05B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$1.06B
EBITDA Margin
-358.45%
TTM Avg
-358.45%
3Y Avg
-358.45%
5Y Avg
-358.45%
Market Cap
$1.02B
EBITDA Margin
8.03%
TTM Avg
9.94%
3Y Avg
10.00%
5Y Avg
10.00%
Market Cap
$1.09B
EBITDA Margin
34.04%
TTM Avg
32.58%
3Y Avg
31.87%
5Y Avg
26.02%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | $1.04B | -1556.38% | -521.77% | -1501.37% | -712.78% |
| Immatics N.V. (IMTX)vs › | $1.04B | -351.42% | -184.18% | -130.50% | -161.84% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | -0.59% | 3.42% | -15.99% | -18.77% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 13.41% | 11.95% | 15.57% | 17.13% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 3.96% | -13.21% | -146.19% | -104.68% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.06B | -358.45% | -358.45% | -358.45% | -358.45% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 8.03% | 9.94% | 10.00% | 10.00% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.09B | 34.04% | 32.58% | 31.87% | 26.02% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $996.94M | N/A | N/A | N/A | N/A |
Gross Margin
79.7%
EBITDA Margin
-1556.4%
Operating Margin
-1576.7%
Net Margin
-321.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -304.15% |
| 2026-03-31 | -903.94% |
| 2025-12-31 | -531.50% |
| 2025-09-30 | -347.50% |
| 2024-09-30 | -8048.29% |
| 2024-06-30 | -149.67% |
| 2024-03-31 | -1567.81% |
| 2023-12-31 | -634.13% |
| 2023-09-30 | -608.38% |
| 2023-06-30 | -1918.35% |
| 2023-03-31 | -968.16% |
| 2022-12-31 | -627.87% |
| 2022-09-30 | -980.31% |
| 2022-06-30 | -725.29% |
| 2022-03-31 | -847.14% |
| 2021-12-31 | -830.82% |
| 2021-09-30 | -938.40% |
| 2021-06-30 | -1294.40% |
| 2021-03-31 | -598.68% |
